GidB mutation as a phylogenetic marker for Q1 cluster Mycobacterium tuberculosis isolates and intermediate-level streptomycin resistance determinant in Lisbon, Portugal

Clinical Microbiology and Infection

Volumn 20, Issue 5, 2014, Pages

  Perdigao J ^a   Macedo, R ^a,b   Machado, D ^c   Silva, C ^a   Jordao L ^e   Couto, I ^c,d   Viveiros, M ^c   Portugal, I ^a  

^a RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^b Public Health Laboratory Mycobacteriology Tuberculosis   (Portugal)

^c INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

^d UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^e NATIONAL INSTITUTE OF HEALTH DR RICARDO JORGE   (Portugal)

Author keywords

M XDR TB; Resistance level; RpsL; Rrs

Indexed keywords

ENDONUCLEASE; STREPTOMYCIN; BIOLOGICAL MARKER;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; CONTROLLED STUDY; GENE MUTATION; GENE SEQUENCE; GENOTYPE; GIDB GENE; MISSENSE MUTATION; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; PORTUGAL; PRIORITY JOURNAL; RPSL GENE; DRUG EFFECTS; GENETICS; HUMAN; LUNG TUBERCULOSIS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

MYCOBACTERIUM TUBERCULOSIS;

BIOLOGICAL MARKERS; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, BACTERIAL; GENOTYPE; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION, MISSENSE; MYCOBACTERIUM TUBERCULOSIS; PHYLOGENY; PORTUGAL; STREPTOMYCIN; TUBERCULOSIS, PULMONARY;

EID: 84901592777     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12392     Document Type: Article

References (30)

1. Menzies D, Benedetti A, Paydar A et al. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med 2009; 6: e1000150.
2. World Health Organization. Treatment of tuberculosis: guidelines, 4th edn. Geneva: World Health Organization, 2010.
3. Perdigao J, Macedo R, Joao I, Fernandes E, Brum L, Portugal I. Multidrug-resistant tuberculosis in Lisbon, Portugal: a molecular epidemiological perspective. Microb Drug Resist 2008; 14: 133-143.
4. Perdigao J, Macedo R, Malaquias A, Ferreira A, Brum L, Portugal I. Genetic analysis of extensively drug-resistant Mycobacterium tuberculosis strains in Lisbon, Portugal. J Antimicrob Chemother 2010; 65: 224-227.
5. Perdigao J, Macedo R, Silva C et al. Tuberculosis drug-resistance in Lisbon, Portugal: a 6-year overview. Clin Microbiol Infect 2011; 17: 1397-1402.
6. Portugal I, Covas MJ, Brum L et al. Outbreak of multiple drug-resistant tuberculosis in Lisbon: detection by restriction fragment length polymorphism analysis. Int J Tuberc Lung Dis 1999; 3: 207-213.
7. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2012. Stockholm: European Centre for Disease Prevention and Control, 2012.
8. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance in Europe 2008. Stockholm: European Centre for Disease Prevention and Control, 2010.
9. Cooksey RC, Morlock GP, McQueen A, Glickman SE, Crawford JT. Characterization of streptomycin resistance mechanisms among Mycobacterium tuberculosis isolates from patients in New York City. Antimicrob Agents Chemother 1996; 40: 1186-1188.
10. Sreevatsan S, Pan X, Stockbauer KE, Williams DL, Kreiswirth BN, Musser JM. Characterization of rpsL and rrs mutations in streptomycin-resistant Mycobacterium tuberculosis isolates from diverse geographic localities. Antimicrob Agents Chemother 1996; 40: 1024-1026.
11. Mieskes KT, Rusch-Gerdes S, Truffot-Pernot C et al. Rapid, simple, and culture-independent detection of rpsL codon 43 mutations that are highly predictive of streptomycin resistance in Mycobacterium tuberculosis. Am J Trop Med Hyg 2000; 63: 56-60.
12. Meier A, Sander P, Schaper KJ, Scholz M, Bottger EC. Correlation of molecular resistance mechanisms and phenotypic resistance levels in streptomycin-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996; 40: 2452-2454.
13. Okamoto S, Tamaru A, Nakajima C et al. Loss of a conserved 7-methylguanosine modification in 16S rRNA confers low-level streptomycin resistance in bacteria. Mol Microbiol 2007; 63: 1096-1106.
14. Wong SY, Lee JS, Kwak HK, Via LE, Boshoff HI, Barry CE 3rd. Mutations in gidB confer low-level streptomycin resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2011; 55: 2515-2522.
15. Mikheil DM, Shippy DC, Eakley NM, Okwumabua OE, Fadl AA. Deletion of gene encoding methyltransferase (gidB) confers high-level antimicrobial resistance in Salmonella. J Antibiot (Tokyo) 2012; 65: 185-192.
16. Springer B, Lucke K, Calligaris-Maibach R, Ritter C, Böttger EC. Quantitative drug susceptibility testing of Mycobacterium tuberculosis by use of MGIT 960 and EpiCenter instrumentation. J Clin Microbiol 2009; 47: 1773-1780.
17. Kirschner P, Bottger EC. Detection of mycobacterium resistance to streptomycin and clarithromycin. In: Persing DH, ed. PCR protocols for emerging infectious diseases. Washington, D.C.: American Society for Microbiology, 1996; 130-137.
18. Supply P, Lesjean S, Savine E, Kremer K, van Soolingen D, Locht C. Automated high-throughput genotyping for study of global epidemiology of Mycobacterium tuberculosis based on mycobacterial interspersed repetitive units. J Clin Microbiol 2001; 39: 3563-3571.
19. Kumar A, Saigal K, Malhotra K, Sinha KM, Taneja B. Structural and functional characterization of Rv2966c protein reveals an RsmD-like methyltransferase from Mycobacterium tuberculosis and the role of its N-terminal domain in target recognition. J Biol Chem 2011; 286: 19652-19661.
20. Romanowski MJ, Bonanno JB, Burley SK. Crystal structure of the Escherichia coli glucose-inhibited division protein B (GidB) reveals a methyltransferase fold. Proteins 2002; 47: 563-567.
21. Feuerriegel S, Oberhauser B, George AG et al. Sequence analysis for detection of first-line drug resistance in Mycobacterium tuberculosis strains from a high-incidence setting. BMC Microbiol 2012; 12: 90.
22. Nhu NT, Lan NT, Phuong NT, van VCN, Farrar J, Caws M. Association of streptomycin resistance mutations with level of drug resistance and Mycobacterium tuberculosis genotypes. Int J Tuberc Lung Dis 2012; 16: 527-531.
23. Spies FS, Ribeiro AW, Ramos DF et al. Streptomycin resistance and lineage-specific polymorphisms in Mycobacterium tuberculosis gidB gene. J Clin Microbiol 2011; 49: 2625-2630.
24. Spies FS, da Silva PE, Ribeiro MO, Rossetti ML, Zaha A. Identification of mutations related to streptomycin resistance in clinical isolates of Mycobacterium tuberculosis and possible involvement of efflux mechanism. Antimicrob Agents Chemother 2008; 52: 2947-2949.
25. David S, Ribeiro DR, Antunes A, Portugal C, Sancho L, de Sousa JG. Contribution of spoligotyping to the characterization of the population structure of Mycobacterium tuberculosis isolates in Portugal. Infect Genet Evol 2007; 7: 609-617.
26. Ioerger TR, Feng Y, Ganesula K et al. Variation among genome sequences of H37Rv strains of Mycobacterium tuberculosis from multiple laboratories. J Bacteriol 2010; 192: 3645-3653.
27. Sharma SK, Kumar S, Saha PK et al. Prevalence of multidrug-resistant tuberculosis among category II pulmonary tuberculosis patients. Indian J Med Res 2011; 133: 312-315.
28. Ponce M, Ugarte-Gil C, Zamudio C, Krapp F, Gotuzzo E, Seas C. Additional evidence to support the phasing-out of treatment category II regimen for pulmonary tuberculosis in Peru. Trans R Soc Trop Med Hyg 2012; 106: 508-510.
29. Furin J, Gegia M, Mitnick C et al. Eliminating the category II retreatment regimen from national tuberculosis programme guidelines: the Georgian experience. Bull World Health Organ 2012; 90: 63-66.
30. Jones-Lopez EC, Ayakaka I, Levin J et al. Effectiveness of the standard WHO recommended retreatment regimen (category II) for tuberculosis in Kampala, Uganda: a prospective cohort study. PLoS Med 2011; 8: e1000427.